ArticleOncotarget2017
XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose.
Marsha L Crochiere et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it
ArticleOncotarget2017
Marsha L Crochiere et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.